Rifkin, R., Spitzer, G., Orloff, G., Mandanas, R., McGaughey, D., Zhan, F., . . . Beveridge, R. (2010). Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma & Leukemia, 10, 186–191.
To compare time to absolute neutrophil count (ANC) recovery for patients treated with filgrastim versus pegfilgrastim.
Patients were randomized to Arm A, pegfilgrastim 6 mg subcutaneously on day 1 after autologous peripheral blood stem cell transplant (PBSCT), or Arm B, weight-based dose of filgrastim subcutaneously from day 1 until either the third consecutive day of ANC greater than 5,000/mm3 or one day of ANC greater than 10,000/mm3 after PBSCT. Duration of treatment was not to be more than 21 days.
Multi-site
Patients were undergoing the active treatment phase of care.
This was a randomized, phase II study.
In the posttransplant setting, pegfilgrastim is preferred over filgrastim based on faster neutrophil recovery, less patient discomfort, and comparable cost.
Small sample size
Pegfilgrastim is favored over filgrastim in patiens undergong NHL posttransplantation due to faster ANC recovery with less patient discomfort at cost that is comparable.